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Abstract: Pharmaceutical R&D process (PR&DP) has been deeply 
investigated by different streams of literature; the interest is due to the strategic 
implication of the related decisions undertaken. The PR&DP has been 
revolutionised by the biotech advent and as a consequence R&D managers 
cannot avoid to consider Open Innovation paradigm during this decision 
process. Starting from a Real Option optimization model available in literature, 
the paper aims at proposing a decision support system (DSS) able to suggest 
the candidate products to be included in the best R&D portfolio varying input 
parameters (resilient products), to provide a products Pareto analysis that aims 
at individuating the products for which it is worthwhile to acquire a deeper 
input parameters knowledge and to draw what if rules. The proposed DSS has 
been applied to a numerical example available in literature and research 
findings show interesting managerial and academic implications.  
Keywords: Open Innovation, Biopharmaceutical industry; R&D portfolio; 
DSS; Real Options 
1  Introduction and problem statement  
Pharmaceutical firms struggle to discover and develop promising compounds before 
competitors do: this will guarantee them to beat competitors in the winner-takes-all patent 
race and, once the drug is introduced in the market, to gain great revenues useful also to 
fund other R&D projects. Thus, due to its focus on innovation, R&D process is extremely 
important in pharmaceutical industry, as it allows a company to achieve high profits and 
growth rates. This importance is witnessed by the financial effort that pharmaceutical 
firms carried out during the last decades to fund R&D activities. In 2009, pharmaceutical 
companies invested US$ 65,3 billion in R&D, 37% more than 5 years before (Phrma 
2011).  
Pharmaceutical industry has experienced the biotech newcomers advent that foster the 
Open Innovation (OI) solutions because of the increasing need of collaboration in order 
to exploit the complementary  resources of incumbents and newcomers. 
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The PR&DP is time and money consuming, it is uncertain and it can be accomplished 
following different alternatives in the continuum between hierarchy (in house 
development) and market (outsourcing R&D), passing through different kinds of 
alliances. As a result, the pharmaceutical R&D decision making process is very 
challenging because it involves different literature topics:  R&D evaluation, portfolio 
selection and Open Innovation.  
 Moreover, PR&DP has a long and dynamic life and further investments depend on the 
success/failure of the previous ones then it is an ideal field of application for Real 
Options Analysis (ROA). ROA is acknowledged as a powerful tool to evaluate uncertain 
projects that have an intrinsic flexibility; so, as Vanhavarbeke et al. (2008) state, it is 
surprising that scholars do not pay attention to the existing  synergy between ROA and 
OI. On the other hand ROA implementation, as widely demonstrated in literature, is 
narrowed to very limited cases because of its perceived complexity (Hartmann and 
Hassan, 2006). Debate about  Real Otpions definition is still open among scholars: we 
refer to the study of McGrath et al. (2004) that gives a very comprehensive definition, 
and starting from their conclusions we can affirm that R&D pharmaceutical process is a 
suitable field of application for ROA as it consists of “specific investments with option-
like properties”. Literature overview offers an interesting example of mathematical 
models, based on ROA,  able to support managers in the selection of the best R&D 
portfolio (Rogers et al., 2002; Rogers et al., 2005; Lo Nigro et al., 2012); however, these 
methods do not support managers in a what if analysis able to understand what happens 
to the best solution if some parameters should change, and this is not an unlikely 
possibility due to the uncertainty that characterises the R&D process. The paper’s 
purpose is to assess a heuristic DSS based on a Real Options optimisation model (Lo 
Nigro et al., 2012) that allows to select the candidate products which should be developed 
in order to maximize the economic value of the portfolio estimated through its Real 
Options Value.  The proposed DSS provides some insights about the change in the 
optimal solution due to the change of some input parameters. The paper is organised as 
follows: the following section, starting from the literature analysis of portfolio  selection 
and real option  models based on portfolio selection, sets the paper’s contribution; section 
3 introduces the research methodology and the numerical example we will refer to; 
section 4 illustrates the obtained  results and shows how the DSS is structured; at the end, 
section 5 focuses on paper findings and further developments. 
2  Portfolio selection literature overview and research contribution 
Portfolio selection  is the problem of allocating capital over a number of available assets 
in order to maximize the return on the investment while minimizing the risk. (Goldfarb 
and Iyengar, 2003). The portfolio selection problem has been one of the most important 
issues in modern finance since the 1950s.  The first model for portfolio optimization was 
developed by Markowitz in 1952; in this model, the return on a portfolio is measured by 
the expected value of the random portfolio return, while associated risk is quantified by 
the variance of  returns’ distribution. In his study, Markowitz, in order to obtain an 
efficient portfolio,  shows how to calculate portfolio which has the highest expected 
return for a given level of risk, or the lowest risk for a given level of expected return.  
Dickinson et al. (2001) and Chien (2002) provide an overview of this literature topic: the 
concept of building business portfolios emerged in the late 1950s  and evolved through 
the 1970s (Souder and Mandakovic, 1986) to become an established planning tool. In the 
1980s and 1990s, companies extended the use of portfolio management into new 
products selection and R&D resource allocation. Many theoretical and practical attempts 
have been made to develop models that would support the process of R&D portfolio 
selection. Early attempts focused on theoretical operations research and management 
science models, usually in the form of a constrained optimization problem (Eilat et al.
2006). 
Many papers have surveyed the existing literature on R&D portfolio selection models: in  
particular Chien (2002) includes a survey of selection procedures and shows that several 
originated from Markowitz’s work.  
According to many scholars, R&D portfolio selection consists in selecting, from a given 
set of candidate projects, a subset of projects,  to maximize an objective function without 
violating the constraints (Baker, 1974; Liberatore and Titus, 1983; Liberatore, 1988; 
Danila, 1989). However, the suggested models to deal with this problem have not found 
widespread use in practice. This phenomenon was observed by Hall and Nauda (1990) 
who noticed that these models require accurate data that are  unavailable in most cases. 
The same phenomenon was also observed by Schmidt and Freeland (1992) and later 
confirmed by Cooper (2001). Farrukh et al. (2000) offer possible explanations for the 
limited implementation of such models in practice and Loch et al. (2001) describe a  
similar experience in a real-world setting. 
Moreover Baker and Freeland (1975) emphasized a drawback of many selection models. 
In their review of existing methods at that time, they concluded that ‘‘one of the most 
important limitations of present R&D project selection models is the inadequate 
treatment of project interrelationships with respect to both value and resource 
utilization.’’ Not much has changed since then.  
The problem of interactions among projects received relatively little attention in 
literature. Most of  the existing studies select R&D projects by evaluating individual  
projects. However, according to Keeney 1987, the combination of individually  good 
projects unnecessarily constitutes the optimal portfolio.  
Several authors remark, in fact, that it is better to evaluate the entire R&D project 
portfolio of a company instead of its single projects, in order to consider the relations and 
the interdependences between them. These interdependences, ignored if projects are 
evaluated one by one, usually deal with limited resources consumption, risk balancing 
and company strategies. 
In his study, Chien (2002) shows a summary of existing studies on the interrelation 
between projects. The author identified several types of interrelation: 
outcome/context/budget interrelation, (Weingarten, 1966); overlap in resource utilization, 
technical or effect interdependence (Aaker and Tyiebyee, 1978); internal and external 
relationships (Gear and Cowie,  1980); cost/outcome /benefit interrelation (Fox et al., 
1984) 
Moreover, according to Dickinson et al.’s study (2001),  the R&D project selection 
model can be divided into three categories : 
1.   Mathematical programming;
2. Classical tools that include  scoring and sorting models and checklists. These methods 
maximize the value of the portfolio through either financial or non-financial measures. 
3. Mapping tools. Mapping portfolio tools use graphical and charting techniques to 
visualize a balanced portfolio. Two-axis diagrams are  typically  used to display the 
trade-off between two criteria: e.g., risk versus reward, probability of success versus 
value, or ease of implementation versus attractiveness.  
In recent years, complex and ad hoc models were developed to capture the actual 
situation of R&D project selection. Beaujon et al. (2001) developed a mixed integer 
programming model, in the form of a multi-dimensional problem, to find an optimal 
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project portfolio and studied the concept of partial funding project and the sensitivity of 
an estimated project value to the selected portfolio. Dickinson et al. (2001) demonstrated 
the use of a dependency matrix representing complex interactions  between projects and 
developed an optimal portfolio model, over multiple time periods,  that was developed 
for the Boeing Company. Moreover Eilat et al. (2006) developed  a methodology for the 
construction and analysis of efficient, effective and balanced portfolios of R&D projects 
with interactions; the methodology is based on an extended data envelopment analysis 
(DEA) model that quantifies some the qualitative concepts embedded in the balanced 
scorecard (BSC) approach. 
Computer-based DSS combines the different approaches into an integrated, interactive, 
manager-friendly tool: computer-based DSS can then be used directly by decision makers 
to analyze what if scenarios for a different parameters set and portfolio compositions 
(Henriksen and Traynor, 1999). Chu  et al. (1996) developed a DSS to help managers to 
select the most appropriate sequences of plans for product research and development 
(R&D) projects that have strict constraints on budget, time, and resources. Moreover 
Ghasemzadeh  and Archer (2000)  discussed the implementation of an organized 
framework for project portfolio selection through a decision support system (DSS), which 
they  call Project Analysis and Selection System (PASS). 
In order to select the optimal mix of R&D projects, the evaluation of each R&D project is 
important. Traditionally, discounted cash flow (DCF) models are the most frequently 
used methods for valuation of R&D projects. However, in the field of R&D projects, 
where high uncertainty and risks are prominent, these methods lose a large amount of 
their effectiveness. In fact, they fail to assess the real value of these projects which 
results, among other things, from the flexibility possessed by the management and from 
the several opportunities these kinds of investment offer. So, in recent years, the real 
options methods have gained growing attention in R&D project evaluation. 
The basic idea of the real options approach is to transfer the sophisticated options pricing 
models used in capital market theory to the valuation of risky R&D projects. 
The real options approach has received great attention in recent years, because an initial 
investment of an R&D project is similar to the purchase of an option on a future 
investment. An R&D project usually involves several phases, and the decision makers 
have the option to stop or defer the project at the end of each phase. In particular, every 
drug in a pharmaceutical pipeline undergoes sequential phases, following the drug 
discovery process in which the drug lead is identified, optimized and tested in animals, 
the drug candidate is taken through three phases of clinical testing: phases I, II and III 
aims at testing efficacy and safety in sample of healthy volunteers or patients. If the drug 
succeeds in all three clinical phases a new drug application (NDA) is submitted to 
approval of FDA; approval allows to launch the drug and commercialize it (Rogers et al., 
2002).Therefore, each phase is an option that is contingent on the earlier exercise of other 
options. If the project is a technical success, it creates the option to make a significantly 
larger investment in the continuing project with relatively higher expected net benefit. If 
the project fails to achieve the technical success, there is no need to commit any further 
resources, and therefore the downside risk is limited to the initial investment cost of the 
R&D project (Wang and Hwang, 2007). 
Biopharmaceutical R&D process is a stepped process that can benefit from the adoption 
of ROA because ROA allows the uncertainty and the flexibility inherent in the process 
itself to be modelled (Vanhaverbeke et al., 2008). 
2.1  Real Options optimal portfolio selection  
As above mentioned, according to several authors it is better to evaluate the entire R&D 
project portfolio of a company instead of its single projects, in order to consider the 
relations and the interdependences between them. These interdependences, ignored if 
projects are evaluated one by one, usually deal with limited resources consumption, risk 
balancing and company strategies. A great contribution in this field to scientific literature 
was brought by Rogers et al. (2002) who developed a stochastic optimization model, 
called OptFolio, able to identify the most valuable projects among the entire R&D project 
portfolio of a company. The aim of this model is to determine the optimal drug 
developmental portfolio that maximizes real options value (ROV), overall value of the 
portfolio, given a set of candidate drugs in various stages of development, estimates of 
the probability of clinical success, duration, investment required for the remaining stages 
and forecasts for future market incomes. Despite being particularly close to reality, 
implementation and use of OptFolio turn out to be very complex. As a matter of fact, a 
pharmaceutical company may find it hard to set its optimal project portfolio solving a 
problem with hundreds of constraints and several dozen thousands of variables, with only 
20 candidate drugs.  
Moreover, OI provides an invaluable tool to balance an innovation portfolio and share 
risk; in the meanwhile an actively managed portfolio demands judgments calls. The 
judgments may well be based on quantitative values and careful measurements but the 
shadow of false positive and false negative judgment persists (Bingham and Spradlin, 
2011) and can be mitigated adopting evaluation method able to overcome the underrated 
problem inherent in the NPV based evaluation method such as the ROA. 
Rogers et al. (2005) proposed a Real Option mathematical model to select the best 
licensing strategy for each product in the R&D portfolio. Lo Nigro et al. (2012) 
developed a mathematical model based on ROA to select a R&D optimal portfolio and 
the best way to develop each of the chosen products following a closed or open 
innovation path, i.e. developing the product in house or through an alliance with a biotech 
firm (licensing in the drug). 
OI is an incentive to integrate technology management and innovation management 
(Licthnthaler, 2011) and it reinforces the need to evaluate the entire portfolio of R&D 
project rather than a stand-alone project.  
Blau et al. 2004 dealt with our research goal and propose a DSS to manage a portfolio of 
interdependent new candidate products in the pharmaceutical industry, and even if they 
acknowledge the suitability of ROA to evaluate the products in the R&D pipeline,  they 
complain the lack, in literature, of ROA based models able to evaluate the entire portfolio 
and to take into account the interdependencies among the products. Actually, an easy to 
implement model with these characteristics is now available in literature (Lo Nigro et al.
2012), so we will refer to it to built our DSS. 
This research aims at developing a DSS for pharmaceutical R&D managers that uses, to 
evaluate each candidate product, the most promising technique (ROA) with a portfolio 
perspective, integrating the three categories in which Dickinson et al. (2001) classified 
R&D projects selection models, to check the influence of each input parameter on the 
optimal solution. The research goal is twofold: firstly to fill in the above highlights 
literature gap about Real Option based DSS for R&D portfolio selection and secondary to 
suggest a general structure for DSS able to support selection process. 
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3  Methodology and numerical example 
The paper object is to assess a method to build a heuristic DSS for a R&D portfolio 
selection. We refer to the proposed model and the numerical example used in Lo Nigro et
al. (2012): besides,  the model, while suggesting the optimal R&D portfolio,  is also able 
to design the financial aspect of the alliance ( the payments and the royalty the pharma 
firm should pour to the biotech one),in order to make the licence attractive for the biotech 
firm if compared with the alternative to bring the product to the market alone without 
alliance: the financial side depends on the value added to the product value by the biotech 
(Ji’) and by the alliance between the pharma and the biotech (Ji). The numerical example 
developed Rogers et al. (2002) and in Lo Nigro et al. (2012) considers 20 candidate 
products: table 1 shows for each product (P) the type, the impending phase and the 
involved input parameters (V0, i.e. the underlying of the call option that evaluates the 
product and is represented by the NPV of the cash flows coming from the product 
commercialisation,  ıi, the cash flows volatility, and  Ji -Ji’  above described; for the 
complete data set of the numerical example please refer to Lo Nigro et al., 2012). 
Table  1  Input parameters for the base solution  
P Type Impending phase V0i  (M$) ıi  Ji  Ji’ 
1 1 50 80% 1,8 1,3 
2 1 100 70% 1,8 1,3 
3 1 200 50% 2 1,5 
4 1 200 60% 2 1,5 
5 1 600 50% 2 1,5 
6 1 
Phase I
100 20% 1,4 1 
7 2 80 50% 1,3 1 
8 2 100 70% 1,7 1,2 
9 2 180 55% 1,9 1,4 
10 2 380 35% 1,9 1,4 
11   2 
Phase II
80 45% 1,5 1,1 
12 3 100 80% 1,2 1 
13 3 400 30% 1,7 1,3 
14 3 
1st  year Phase III 
700 40% 1,6 1,3 
15 4   500 35% 1,4 1,2 
16 4 
2nd year  
Phase III 300 100% 1,2 1,1 
17 5  350    
18 5 
1st  year  
FDA  Approv. 550    
19 6  800    
20 6 
2nd year 
FDA Approv. 1150    
The proposed methodology to build up the DSS is driven by the problems that managers 
are called to answer during the selection process of a R&D portfolio.  
The considered mathematical model refers to a complex decision and it is made harder to 
tackle with because of the evaluation method chosen: the ROA.  
In particular, for the numerical example at hand, managers should be interested in 
understanding how much robust is the obtained solution for the considered input data (the 
last four columns of table 1). 
The relationship between each of these parameters and the selected portfolio is not a 
linear one because the impact of each parameter on the objective function is not a linear 
one. To some extent we can refer to the influence of real options parameters to the call 
value: the so called Greeks and in particular Delta, ',  that measures the rate of change of 
option value with respect to changes in the underlying asset's price (Gaardner, 2007). but 
the model is a constrained optimization one: i.e. the interdependencies among the 
products play a fundamental role.  
So, a sensitivity analysis, in its classical version, is not the best way to understand what 
could happen to the best solution if the input parameters would be changed. 
4  The proposed DSS 
The proposed DSS has been built in three steps that cover the three portfolio selection 
model classes suggested by Dickinson et al. (2001). 
STEP 1: Mathematical Programming 
In order to become more familiar with the model optimization logic, we built a design of  
experiments to test how, varying the input parameters, the optimal portfolio changes. We 
vary the input parameters in the range proposed in the numerical example: for each 
drug’s type (type1-type6) we individuate the minimum and maximum value of the input 
parameters considered (V0, Ji -Ji’  , ıi) and consequently we obtained 104 experiments 
(for products 17-20, that are in the last phase of development, the evaluation method used 
is the NPV, so that Ji -Ji’  and ıiare not relevant). 
We run the optimisation model for the experiments listed in table 2. We analysed the 
results in order to obtain useful insights for managerial decisions; our considerations are 
formulated comparing the optimal solution, obtained with  the parameters set of table 1 
(that from now on, it will be called base solution and consists in a portfolio of 10 
products: six to be developed licensing in them, 3,5,6,9,10 and 11, and 5 to be developed 
in house, namely products 14,15,16 and 19) to the optimal solutions of each of the 104 
experiments.  
STEP 2 Screening and Sorting 
As there is a high number of products and parameters involved in the problem, it could be 
useful to individuate the most important products, i.e. the products that are more 
frequently chosen or that give an important financial contribution to Real Options Value 
(ROV) of the selected portfolio. Experiments’ results highlight as some products belong 
to many best portfolios and others do not: so we found the “contribution” in terms of 
ROV of each product to the obtained solutions (without considering the possibility 
offered by some products to finance other products) and then we sorted the products out 
basing on this value (i.e contribution). In this way we can implement the Pareto analysis 
and individuate products that mostly  contribute to the best solution: we can notice that 
P19-P15-P5-P14 (class A) account for the 66%  of the overall ROVs, P10-P20-P16-P9-
P3 (class B) for 29% and the remaining ones (class C) for just 5% We tried  a Pareto 
analysis also on the frequency of each product that is part of optimal portfolios, but in 
this case, the distribution is quite uniform: so  a Pareto analysis is not suitable. 
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Table  2  Design of experiments 
 Var. levels V0 ʍi JiͲJi’ 
P1 
MIN E1 E2 E3 
MAX E4 E5 E6 
P2 
MIN E7 E8 E9 
MAX E10 E11 E12 
P3 
MIN E13 E14 E15 
MAX E16 E17 E18 
P4 
MIN E19 E20 E21 
MAX E22 E23 E24 
P5 
MIN E25 E26 E27 
MAX E28 E29 E30 
P6 
MIN E31 E32 E33 
MAX E34 E35 E36 
P7 
MIN E37 E38 E39 
MAX E40 E41 E42 
P8 
MIN E43 E44 E45 
MAX E46 E47 E48 
P9 
MIN E49 E50 E51 
MAX E52 E53 E54 
P10 
MIN E55 E56 E57 
MAX E58 E59 E60 
P11 
MIN E61 E62 E63 
MAX E64 E65 E66 
P12 
MIN E67 E68 E69 
MAX E70 E71 E72 
P13 
MIN E73 E74 E75 
MAX E76 E77 E78 
P14 
MIN E79 E80 E81 
MAX E82 E83 E84 
P15 
MIN E85 E86 E87 
MAX E88 E89 E90 
P16 
MIN E91 E92 E93 
MAX E94 E95 E96 
P17 
MIN E97   
MAX E98   
P18 
MIN E99   
MAX E100   
P19 
MIN E101   
MAX E102   
P20 
MIN E103   
MAX E104   

The Pareto analysis on the product’s contribution to the value of optimal portfolios 
allows to focus the attention  on the products that have an important weight in the overall 
obtained optimal portfolios. This screening task is useful to concentrate the effort of time 
consuming deeper analyses on products belonging to class A. 
Figure 1 Pareto analysis of the product portfolio value contribution. 
STEP THREE  What if  rules and Mapping 
It is also interesting to understand the impact of each parameter to the optimal portfolio: 
in particular we can distinguish between  direct effect and secondary effect. We refer to 
direct effect to indicate the impact the product i parameter has on the product i itself  and 
we refer to secondary effect to indicate its impact on the 19 remaining drugs: for example 
in E4 (table 2) the parameter changed is V0 for the product 1 that is equal to the 
maximum of the V0 for the type 1’s products (V0=600) and it can influence either product 
1 choice (direct effect) or P2-P19 choice (secondary effect).   
The obtained optimal solution for E4 suggests to develop in house P1-P15-P16 and P19 
and to licensing-in P2-P5-P9-P10-P11-P13. 
We can observe that, comparing this solution to the base one, a higher V0 for product 1 
has a direct consequence on product 1 that is chosen to be developed in house and  
secondary effect on other products (product 3, 6 and 14 don’t belong no more to the best 
portfolio while products 2 and 13 are chosen): it is a kind of substitution effect (Pindyck 
and Rubinfeld, 2008). The secondary effects are very hard to understand, but to this 
purpose, the above proposed Pareto analysis combined with the what if  rules (below 
proposed) , could be helpful.  
A direct effect analysis on  the products of the base solution, that belong to class A and 
class B of the Pareto analysis,  allows to gain some insights. 
In particular we can observe for P15 (E85 and E88) for higher values of V0 the model 
suggests to develop it in house,  while for the minimum value to licence in it; for P3 (E13 
and E16) for the lowest value of V0 the model suggests do not to include it in the optimal 
portfolio, otherwise to licence-in  it.   
Looking at the solutions obtained for E25 and E28 (P5), E31 and E34  (P6), E55 and E58 
(P10), E91 and E94 (P16), E101 and E102 (P19) no direct effect can be observed and 
then the base solution is robust. 
These considerations allow to formulate the following what if rule:  
Rule 1 The higher the value of V0 the higher the opportunity to select the drug and 
to develop it in house.   
This is an expected result that agree with the influence of the underlying (V0) on the call 
value as foreseen by 'the higher the value of V0 of a product, the higher its real option 
value.  
Pareto Analysis 
0
66%
95% 100%
0
0,2
0,4
0,6
0,8
1
0 P19-P15-P5-P14 P10-P20-P16-P9-P3 P6-P11P13-P2-P4-P1-P7-P8
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As far as Ji -Ji’ are concerned a lower value of Ji -Ji’ (for P3, P6, P9, P10 and P11) causes 
the exclusion of the product from the optimal portfolio or the suggestion to develop it in 
house (P5 and P10). 
This is another  expected result, because the licensing-in is a convenient solution to 
develop a product if the alliance adds value to the product: moreover the analysis 
suggests that P5 and P10 are valuable products to maintain in the portfolio and to: 
develop in house, if licensing is not a convenient alternative  (low value for Ji -Ji’); the 
other products are no more in the optimal portfolio if the licensing  solution is not 
convenient any more. 
These considerations allow to formulate the following what if rule:  
Rule 2 The higher the value of Ji -Ji’the higher the opportunity to select licensable 
drugs and to licence-in them:
The influence of ķi is limited to two cases: we can conclude that, in  the considered 
example,  the base solution is robust if ķi varies. 
The results can also give interesting suggestions on the portfolio mix:  figure 2 shows a 4 
quadrants bubble chart; the four quadrants are obtained combining two variables with two 
levels each: quadrant 1 refers to products of type 1 or 2 developed in alliance, quadrant 2 
refers to products of type 3, 4, 5 or 6 developed in alliance; quadrant 3 refers to products 
of type 3, 4, 5 or 6 developed in house and finally, quadrant 4, refers to products of type 1 
or 2 developed in house. For each quadrant the axes are respectively the average 
contribution of the product to the overall optimal solutions obtained for experiments 
listed in table 2 and the times the product appears in the optimal solutions of the same 
experiments: for example in quadrant 4 each bubble refers to a product i of type 1 or type 
2 and to the optimal solutions in which it is developed in house (HOSsi), the bubble  is 
centred according to the average contribution of the product i to its HOSsi and to the 
number of HOSsi for the considered product and its area is proportional to the overall 
contribution of product i  to the optimal considered solutions (HOSsi).
As shown in figure 2 (Q1) type 1 e type 2 products, which have the impending phase in 
the first ones considered in the numerical example, when selected, are developed 
licensing in them; while type 3, 4, 5 and 6 products, if selected, are developed in house 
(quadrant3) (Bianchi et al., 2011). Some exceptions are represented by P13 (Q2) that is 
of type 3 and, if selected, is developed in alliance (instead of in house) and by P1, P10 
(Q4) and P15 (Q2) that, for just 1 experiment, are selected and developed in the opposite 
expected way: P13 goes into the optimal portfolios because of  secondary effects, while 
P1 is developed in house when its V0 assumes the highest value; P10 when Ji -Ji’ achieve 
the lowest value and then the alliance is not a promising alternative, P15 is developed in 
alliance when its V0 is equal to the minimum value (direct effect). Moreover, figure 2 
gives an alternative graphical representation of the Pareto analysis according to the 
mapping methods. 
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5  Conclusions
The paper aims at supporting managers in Innovation Management in the pharmaceutical 
industry, in particular during the selection process of the R&D candidate products to 
develop. This is a constrained problem, limited resources cannot allow to develop all the 
potential candidates and it obliges to adopt a portfolio perspective; moreover some R&D 
processes have characteristics that require advanced evaluation methods like ROA. 
Literature offers mathematical models to tackle with the selection process in the depicted 
scenario (Real Option base R&D evaluation of interdependent projects). We propose a 
DSS articulated in three steps that is able to: design an experimental plan to test the 
influence of uncertain parameters of the input data set on the optimal solution, analyse 
the obtained results from the experimental plans in order to obtain what if rules and map 
the results in an effective way. Moreover the suggested what if rules confirm theoretical 
knowledge about ROA and OI: the first rule confirms the importance of the underlying 
value of the real option of each candidate product in selecting the product itself, while the 
second one confirms the importance of complementary resources in OI.  
Research findings show interesting managerial and academic implications: the main 
driver in product robustness (resilience in the optimal portfolio) and in determining the 
way the  product is developed (in house or licensing it) is the net present value of cash 
flows coming from the commercialization of the drug (that represents the underlying of 
the related call option); the added value from the potential partners, expressed by Ji -Ji’, 
plays an important role in products selection, too. 
The proposed methodology offers general guidelines to built a DSS that can be applied to 
mathematical programming with goal similar to the one we dealt with. 
Further developments aim at investigating the diversification side of the problem and 
then at obtaining a risk-return efficient frontier: in order to accomplish this task 
correlation between each couple of products should be known. This is an interesting task 
because, as demonstrated in van Bekkum et al. (2009), correlation among R&D products 
This paper was presented at The XXIII ISPIM Conference – Action for Innovation: Innovating 
from Experience – in Barcelona, Spain on 17-20 June 2012. The publication is available to ISPIM 
members at www.ispim.org.
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with Real Options characteristics act differently than usually and in particular negative 
correlation only slightly reduces portfolio risk. 
.Moreover a fuzzy version of the mathematical model, and then of the DSS, could 
properly tackle with the uncertainty of the involved parameters. 
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